Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder.
2-Arachidonoylglycerol (2-AG)
Anandamide (AEA)
Autism spectrum disorder
Endocannabinoid system
Journal
Neuromolecular medicine
ISSN: 1559-1174
Titre abrégé: Neuromolecular Med
Pays: United States
ID NLM: 101135365
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
08
12
2023
accepted:
04
03
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well as the presence of restricted and repetitive facets of behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over the past few decades, a sizable number of studies have been conducted to enhance our understanding of the pathophysiology of ASD. Preclinical rat models have proven to be extremely valuable in simulating and analyzing the roles of a wide range of established environmental and genetic factors. Recent research has also demonstrated the significant involvement of the endocannabinoid system (ECS) in the pathogenesis of several neuropsychiatric diseases, including ASD. In fact, the ECS has the potential to regulate a multitude of metabolic and cellular pathways associated with autism, including the immune system. Moreover, the ECS has emerged as a promising target for intervention with high predictive validity. Particularly noteworthy are resent preclinical studies in rodents, which describe the onset of ASD-like symptoms after various genetic or pharmacological interventions targeting the ECS, providing encouraging evidence for further exploration in this area.
Identifiants
pubmed: 38744725
doi: 10.1007/s12017-024-08781-6
pii: 10.1007/s12017-024-08781-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : King Abdulaziz University
ID : IFFPP-24-22
Informations de copyright
© 2024. The Author(s).
Références
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022). An update on psychopharmacological treatment of autism spectrum disorder. Neurotherapeutics, 19(1), 248–262. https://doi.org/10.1007/s13311-022-01183-1
doi: 10.1007/s13311-022-01183-1
pubmed: 35029811
pmcid: 9130393
Aran, A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., Schnapp, A., Cassuto, H., Wattad, N., & Tam, J. (2019). Lower circulating endocannabinoid levels in children with autism spectrum disorder. Molecular Autism, 10(1), 1–11.
doi: 10.1186/s13229-019-0256-6
Atwood, B. K., & Mackie, K. (2010). CB2: A cannabinoid receptor with an identity crisis. British Journal of Pharmacology, 160(3), 467–479.
pubmed: 20590558
pmcid: 2931549
doi: 10.1111/j.1476-5381.2010.00729.x
Atwood, B. K., Straiker, A., & Mackie, K. (2012a). CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), 16–20. https://doi.org/10.1016/j.pnpbp.2011.12.001
doi: 10.1016/j.pnpbp.2011.12.001
pubmed: 22197668
Atwood, B. K., Wager-Miller, J., Haskins, C., Straiker, A., & Mackie, K. (2012b). Functional selectivity in CB2 cannabinoid receptor signaling and regulation: Implications for the therapeutic potential of CB2 ligands. Molecular Pharmacology, 81(2), 250–263.
pubmed: 22064678
pmcid: 3263955
doi: 10.1124/mol.111.074013
Bailone, R. L., Fukushima, H. C. S., De Aguiar, L. K., & Borra, R. C. (2022). The endocannabinoid system in Zebrafish and its potential to study the effects of Cannabis in humans. Laboratory Animal Research, 38(1), 1–12.
doi: 10.1186/s42826-022-00116-5
Baron-Cohen, S. (2004). Autism: Research into causes and intervention. Pediatric Rehabilitation, 7(2), 73–78.
pubmed: 15204577
doi: 10.1080/13638490310001654790
Berghuis, P., Rajnicek, A. M., Morozov, Y. M., Ross, R. A., Mulder, J., Urbán, G. M., Monory, K., Marsicano, G., Matteoli, M., Canty, A., Irving, A. J., Katona, I., Yanagawa, Y., Rakic, P., Lutz, B., Mackie, K., & Harkany, T. (2007). Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science, 316(5828), 1212–1216. https://doi.org/10.1126/science.1137406
doi: 10.1126/science.1137406
pubmed: 17525344
Bou Khalil, R. (2012). Would some cannabinoids ameliorate symptoms of autism? European Child & Adolescent Psychiatry, 21(4), 237–238.
doi: 10.1007/s00787-012-0255-z
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., De La Torre, R., & Dierssen, M. (2013). Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nature Medicine, 19(5), 603–607.
pubmed: 23542787
doi: 10.1038/nm.3127
Carrier, E. J., Kearn, C. S., Barkmeier, A. J., Breese, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., & Hillard, C. J. (2004). Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Molecular Pharmacology, 65(4), 999–1007. https://doi.org/10.1124/mol.65.4.999
doi: 10.1124/mol.65.4.999
pubmed: 15044630
Chakrabarti, B., Kent, L., Suckling, J., Bullmore, E., & Baron-Cohen, S. (2006). Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. European Journal of Neuroscience, 23(7), 1944–1948.
pubmed: 16623851
doi: 10.1111/j.1460-9568.2006.04697.x
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997). Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proceedings of the National Academy of Sciences USA, 94(10), 5401–5404.
doi: 10.1073/pnas.94.10.5401
Cording, K. R., & Bateup, H. S. (2023). Altered motor learning and coordination in mouse models of autism spectrum disorder. Frontiers in Cellular Neuroscience, 17, 1270489. https://doi.org/10.3389/fncel.2023.1270489
doi: 10.3389/fncel.2023.1270489
pubmed: 38026686
pmcid: 10663323
Cristino, L., Bisogno, T., & Di Marzo, V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology, 16(1), 9–29. https://doi.org/10.1038/s41582-019-0284-z
doi: 10.1038/s41582-019-0284-z
pubmed: 31831863
Di Marco, B., Bonaccorso, C. M., Aloisi, E., Antoni, S., & Catania, M. V. (2016). Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: A neuro-immune perspective. CNS & Neurological Disorders-Drug Targets, 15(4), 448–463.
doi: 10.2174/1871527315666160321105039
Do, Y., McKallip, R. J., Nagarkatti, M., & Nagarkatti, P. S. (2004). Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: Novel role for endogenous and exogenous cannabinoids in immunoregulation. The Journal of Immunology, 173(4), 2373–2382. https://doi.org/10.4049/jimmunol.173.4.2373
doi: 10.4049/jimmunol.173.4.2373
pubmed: 15294950
Doenni, V. M., Gray, J. M., Song, C. M., Patel, S., Hill, M. N., & Pittman, Q. J. (2016). Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. Brain, Behavior, and Immunity, 58, 237–247. https://doi.org/10.1016/j.bbi.2016.07.152
doi: 10.1016/j.bbi.2016.07.152
pubmed: 27453335
pmcid: 5461973
Domschke, K., Dannlowski, U., Ohrmann, P., Lawford, B., Bauer, J., Kugel, H., Heindel, W., Young, R., Morris, P., & Arolt, V. (2008). Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in major depression. European Neuropsychopharmacology, 18(10), 751–759.
pubmed: 18579347
doi: 10.1016/j.euroneuro.2008.05.003
Efron, D., & Taylor, K. (2023). Medicinal Cannabis for paediatric developmental, behavioural and mental health disorders. International Journal of Environmental Research and Public Health, 20(8), 5430.
pubmed: 37107712
pmcid: 10138057
doi: 10.3390/ijerph20085430
Elphick, M. R. (2012). The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society b: Biological Sciences, 367(1607), 3201–3215.
doi: 10.1098/rstb.2011.0394
Etherton, M., Földy, C., Sharma, M., Tabuchi, K., Liu, X., Shamloo, M., Malenka, R. C., & Südhof, T. C. (2011). Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proceedings of the National Academy of Sciences USA, 108(33), 13764–13769.
doi: 10.1073/pnas.1111093108
Fingerle-Rowson, G. R., & Bucala, R. (2001). Neuroendocrine properties of macrophage migration inhibitory factor (MIF). Immunology and Cell Biology, 79(4), 368–375. https://doi.org/10.1046/j.1440-1711.2001.01024.x
doi: 10.1046/j.1440-1711.2001.01024.x
pubmed: 11488984
Fong, T. M., & Heymsfield, S. B. (2009). Cannabinoid-1 receptor inverse agonists: Current understanding of mechanism of action and unanswered questions. International Journal of Obesity, 33(9), 947–955. https://doi.org/10.1038/ijo.2009.132
doi: 10.1038/ijo.2009.132
pubmed: 19597516
Freund, T. F., Katona, I., & Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews, 83(3), 1017–1066. https://doi.org/10.1152/physrev.00004.2003
doi: 10.1152/physrev.00004.2003
pubmed: 12843414
Garber, K. B., Visootsak, J., & Warren, S. T. (2008). Fragile X syndrome. European Journal of Human Genetics, 16(6), 666–672.
pubmed: 18398441
doi: 10.1038/ejhg.2008.61
Garcia-Gutierrez, M. S., Navarrete, F., Navarro, G., Reyes-Resina, I., Franco, R., Lanciego, J. L., Giner, S., Manzanares, J. (2018). Alterations in gene and protein expression of cannabinoid cb2 and gpr55 receptors in the dorsolateral prefrontal cortex of suicide victims. Neurotherapeutics. (2018) 15, 796–806. https://doi.org/10.1007/s13311-018-0610-y
doi: 10.3390/ijms19030833
Geschwind, D. H. (2008). Autism: Many genes, common pathways? Cell, 135(3), 391–395. https://doi.org/10.1016/j.cell.2008.10.016
doi: 10.1016/j.cell.2008.10.016
pubmed: 18984147
pmcid: 2756410
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., & Stanley, E. R. (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 330(6005), 841–845.
pubmed: 20966214
pmcid: 3719181
doi: 10.1126/science.1194637
Ginhoux, F., Lim, S., Hoeffel, G., Low, D., & Huber, T. (2013). Origin and differentiation of microglia. Frontiers in Cellular Neuroscience, 2013(7), 45.
Gomez Perdiguero, E., Schulz, C., & Geissmann, F. (2013). Development and homeostasis of “resident” myeloid cells: The case of the microglia. Glia, 61(1), 112–120. https://doi.org/10.1002/glia.22393
doi: 10.1002/glia.22393
pubmed: 22847963
Gomis-González, M., Busquets-Garcia, A., Matute, C., Maldonado, R., Mato, S., & Ozaita, A. (2016). Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model. Genes (basel). https://doi.org/10.3390/genes7090056
doi: 10.3390/genes7090056
pubmed: 27589806
Grigorenko, E. L., Han, S. S., Yrigollen, C. M., Leng, L., Mizue, Y., Anderson, G. M., Mulder, E. J., de Bildt, A., Minderaa, R. B., Volkmar, F. R., Chang, J. T., & Bucala, R. (2008). Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics, 122(2), e438-445. https://doi.org/10.1542/peds.2007-3604
doi: 10.1542/peds.2007-3604
pubmed: 18676531
Gunn, J. K., Rosales, C. B., Center, K. E., Nuñez, A., Gibson, S. J., Christ, C., & Ehiri, J. E. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. British Medical Journal Open, 6(4), e009986. https://doi.org/10.1136/bmjopen-2015-009986
doi: 10.1136/bmjopen-2015-009986
Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Molecular Autism, 1(1), 1–14.
doi: 10.1186/2040-2392-1-12
Hansel, C. (2019). Deregulation of synaptic plasticity in autism. Neuroscience Letters, 688, 58–61. https://doi.org/10.1016/j.neulet.2018.02.003
doi: 10.1016/j.neulet.2018.02.003
pubmed: 29421544
Hasumi, A., Maeda, H., & Yoshida, K.-I. (2020). Analyzing cannabinoid-induced abnormal behavior in a zebrafish model. PLoS ONE, 15(10), e0236606.
pubmed: 33031370
pmcid: 7544081
doi: 10.1371/journal.pone.0236606
Heussler, H., Cohen, J., Silove, N., Tich, N., Bonn-Miller, M. O., Du, W., O’Neill, C., & Sebree, T. (2019). A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. Journal of Neurodevelopmental Disorders, 11(1), 1–9.
doi: 10.1186/s11689-019-9277-x
Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023). The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Psychological Medicine, 53(15), 7006–7024.
pubmed: 37671673
pmcid: 10719691
doi: 10.1017/S0033291723002465
Hu, C., Li, H., Li, J., Luo, X., & Hao, Y. (2022). Microglia: Synaptic modulator in autism spectrum disorder. Front Psychiatry, 13, 958661. https://doi.org/10.3389/fpsyt.2022.958661
doi: 10.3389/fpsyt.2022.958661
pubmed: 36465285
pmcid: 9714329
Hughes, H., Moreno, R., & Ashwood, P. (2023). Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD). Brain, Behavior, and Immunity, 108, 245–254.
pubmed: 36494048
doi: 10.1016/j.bbi.2022.12.001
Hutsler, J. J., & Zhang, H. (2010). Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Research, 1309, 83–94.
pubmed: 19896929
doi: 10.1016/j.brainres.2009.09.120
Ishiguro, H., Iwasaki, S., Teasenfitz, L., Higuchi, S., Horiuchi, Y., Saito, T., Arinami, T., & Onaivi, E. (2007). Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. The Pharmacogenomics Journal, 7(6), 380–385.
pubmed: 17189959
doi: 10.1038/sj.tpj.6500431
Jamain, S., Radyushkin, K., Hammerschmidt, K., Granon, S., Boretius, S., Varoqueaux, F., Ramanantsoa, N., Gallego, J., Ronnenberg, A., & Winter, D. (2008). Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proceedings of the National Academy of Sciences USA, 105(5), 1710–1715.
doi: 10.1073/pnas.0711555105
Janda, E., Boi, L., & Carta, A. R. (2018). Microglial phagocytosis and its regulation: A therapeutic target in Parkinson’s disease? Frontiers in Molecular Neuroscience, 11, 144.
pubmed: 29755317
pmcid: 5934476
doi: 10.3389/fnmol.2018.00144
Jung, K.-M., Sepers, M., Henstridge, C. M., Lassalle, O., Neuhofer, D., Martin, H., Ginger, M., Frick, A., DiPatrizio, N. V., & Mackie, K. (2012). Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nature Communications, 3(1), 1–11.
doi: 10.1038/ncomms2045
Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., Essig, J., Erxlebe, E., Bab, I., & Kubisch, C. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Human Molecular Genetics, 14(22), 3389–3396.
pubmed: 16204352
doi: 10.1093/hmg/ddi370
Kazdoba, T. M., Leach, P. T., Silverman, J. L., & Crawley, J. N. (2014). Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable & Rare Diseases Research, 3(4), 118–133.
doi: 10.5582/irdr.2014.01024
Kerr, D. M., Downey, L., Conboy, M., Finn, D. P., & Roche, M. (2013). Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behavioural Brain Research, 249, 124–132. https://doi.org/10.1016/j.bbr.2013.04.043
doi: 10.1016/j.bbr.2013.04.043
pubmed: 23643692
Kerr, D. M., Gilmartin, A., & Roche, M. (2016). Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. Pharmacological Research, 113(Pt A), 228–235. https://doi.org/10.1016/j.phrs.2016.08.033
doi: 10.1016/j.phrs.2016.08.033
pubmed: 27592249
Kibret, B. G., Canseco-Alba, A., Onaivi, E. S., & Engidawork, E. (2023). Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. Frontiers in Behavioral Neuroscience, 17, 1137957.
pubmed: 37009000
pmcid: 10061032
doi: 10.3389/fnbeh.2023.1137957
Killestein, J., Hoogervorst, E. L., Reif, M., Blauw, B., Smits, M., Uitdehaag, B. M., Nagelkerken, L., & Polman, C. H. (2003). Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. Journal of Neuroimmunology, 137(1–2), 140–143. https://doi.org/10.1016/s0165-5728(03)00045-6
doi: 10.1016/s0165-5728(03)00045-6
pubmed: 12667658
Kim, H. J., Cho, M. H., Shim, W. H., Kim, J. K., Jeon, E. Y., Kim, D. H., & Yoon, S. Y. (2017). Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. Molecular Psychiatry, 22(11), 1576–1584. https://doi.org/10.1038/mp.2016.103
doi: 10.1038/mp.2016.103
pubmed: 27400854
Klee, E. W., Schneider, H., Clark, K. J., Cousin, M. A., Ebbert, J. O., Hooten, W. M., Karpyak, V. M., Warner, D. O., & Ekker, S. C. (2012). Zebrafish: A model for the study of addiction genetics. Human Genetics, 131(6), 977–1008.
pubmed: 22207143
doi: 10.1007/s00439-011-1128-0
Lam, C., Rastegar, S., & Strähle, U. (2006). Distribution of cannabinoid receptor 1 in the CNS of zebrafish. Neuroscience, 138(1), 83–95.
pubmed: 16368195
doi: 10.1016/j.neuroscience.2005.10.069
Lenz, K. M., & Nelson, L. H. (2018). Microglia and beyond: innate immune cells as regulators of brain development and behavioral function. Frontiers in Immunology, 9, 698. https://doi.org/10.3389/fimmu.2018.00698
doi: 10.3389/fimmu.2018.00698
pubmed: 29706957
pmcid: 5908908
Lombardi, L. M., Baker, S. A., & Zoghbi, H. Y. (2015). MECP2 disorders: From the clinic to mice and back. The Journal of Clinical Investigation, 125(8), 2914–2923. https://doi.org/10.1172/jci78167
doi: 10.1172/jci78167
pubmed: 26237041
pmcid: 4563741
Maccarrone, M., Rossi, S., Bari, M., De Chiara, V., Rapino, C., Musella, A., Bernardi, G., Bagni, C., & Centonze, D. (2010). Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology, 35(7), 1500–1509. https://doi.org/10.1038/npp.2010.19
doi: 10.1038/npp.2010.19
pubmed: 20393458
pmcid: 3055456
Mackie, K. (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. In R. G. Pertwee (Ed.), Cannabinoids (pp. 299–325). Springer.
doi: 10.1007/3-540-26573-2_10
Maestroni, G. J. (2004). The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. The FASEB Journal, 18(15), 1914–1916. https://doi.org/10.1096/fj.04-2190fje
doi: 10.1096/fj.04-2190fje
pubmed: 15385435
Mangiatordi, G. F., Cavalluzzi, M. M., Delre, P., Lamanna, G., Lumuscio, M. C., Saviano, M., Majoral, J.-P., Mignani, S., Duranti, A., & Lentini, G. (2023). Endocannabinoid degradation enzyme inhibitors as potential antipsychotics: A medicinal chemistry perspective. Biomedicines, 11(2), 469.
pubmed: 36831006
pmcid: 9953700
doi: 10.3390/biomedicines11020469
Marco, E. M., & Laviola, G. (2012). The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives. Journal of Psychopharmacology, 26(1), 150–163.
pubmed: 21693551
doi: 10.1177/0269881111408459
Marsicano, G., & Lutz, B. (2006). Neuromodulatory functions of the endocannabinoid system. Journal of Endocrinological Investigation, 29(3), 27.
pubmed: 16751707
Matsuda, L. A. (1997). Molecular aspects of cannabinoid receptors. Critical Reviews™ in Neurobiology, 11(2–3), 143.
pubmed: 9209828
doi: 10.1615/CritRevNeurobiol.v11.i2-3.30
McOmish, C. E., Burrows, E. L., & Hannan, A. J. (2014). Identifying novel interventional strategies for psychiatric disorders: Integrating genomics, ‘enviromics’ and gene–environment interactions in valid preclinical models. British Journal of Pharmacology, 171(20), 4719–4728. https://doi.org/10.1111/bph.12783
doi: 10.1111/bph.12783
pubmed: 24846457
pmcid: 4209939
Mechoulam, R. (2023). A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. Annual Review of Pharmacology and Toxicology, 63, 1–13.
pubmed: 35850522
doi: 10.1146/annurev-pharmtox-051921-083709
Miller, F. D., & Gauthier, A. S. (2007). Timing is everything: Making neurons versus glia in the developing cortex. Neuron, 54(3), 357–369. https://doi.org/10.1016/j.neuron.2007.04.019
doi: 10.1016/j.neuron.2007.04.019
pubmed: 17481390
Mondal, A., Sharma, R., Abiha, U., Ahmad, F., Karan, A., Jayaraj, R. L., & Sundar, V. (2023). A Spectrum of solutions: Unveiling non-pharmacological approaches to manage autism spectrum disorder. Medicina, 59(9), 1584.
pubmed: 37763703
pmcid: 10536417
doi: 10.3390/medicina59091584
Morcuende, A., García-Gutiérrez, M. S., Tambaro, S., Nieto, E., Manzanares, J., & Femenia, T. (2022). Immunomodulatory role of CB2 receptors in emotional and cognitive disorders. Frontiers in Psychiatry, 13, 866052.
Morgan, J. T., Chana, G., Pardo, C. A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., & Everall, I. P. (2010). Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biological Psychiatry, 68(4), 368–376.
pubmed: 20674603
doi: 10.1016/j.biopsych.2010.05.024
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.
pubmed: 7689702
doi: 10.1038/365061a0
Nguyen, P. T., Schmid, C. L., Raehal, K. M., Selley, D. E., Bohn, L. M., & Sim-Selley, L. J. (2012). β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biological Psychiatry, 71(8), 714–724. https://doi.org/10.1016/j.biopsych.2011.11.027
doi: 10.1016/j.biopsych.2011.11.027
pubmed: 22264443
pmcid: 3319102
Oka, S., Yanagimoto, S., Ikeda, S., Gokoh, M., Kishimoto, S., Waku, K., Ishima, Y., & Sugiura, T. (2005). Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. Journal of Biological Chemistry, 280(18), 18488–18497. https://doi.org/10.1074/jbc.M413260200
doi: 10.1074/jbc.M413260200
pubmed: 15749716
Onaivi, E. S. (2006). Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology, 54(4), 231–246.
pubmed: 17356307
doi: 10.1159/000100778
Onaivi, E. S., Ishiguro, H., Gong, J. P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., Brusco, A., Akinshola, B. E., Hope, B., Lujilde, J., Inada, T., Iwasaki, S., Macharia, D., Teasenfitz, L., Arinami, T., Uhl, G. R. (2008). Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One. 3, e1640. https://doi.org/10.1371/journal.pone.0001640
pubmed: 18286196
pmcid: 2241668
doi: 10.1371/journal.pone.0001640
Onaivi, E., Ishiguro, H., Sgro, S., & Leonard, C. (2013). Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. Journal of Drug and Alcohol Research, 2(1), 1–11.
doi: 10.4303/jdar/235714
Pardo, C. A., & Eberhart, C. G. (2007). The neurobiology of autism. Brain Pathology, 17(4), 434–447. https://doi.org/10.1111/j.1750-3639.2007.00102.x
doi: 10.1111/j.1750-3639.2007.00102.x
pubmed: 17919129
pmcid: 8095519
Parrella, N.-F., Hill, A. T., Enticott, P. G., Barhoun, P., Bower, I. S., & Ford, T. C. (2023). A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacology Biochemistry and Behavior, 230, 173607. https://doi.org/10.1016/j.pbb.2023.173607
doi: 10.1016/j.pbb.2023.173607
pubmed: 37543051
Pascucci, T., Colamartino, M., Fiori, E., Sacco, R., Coviello, A., Ventura, R., Puglisi-Allegra, S., Turriziani, L., & Persico, A. M. (2020). P-cresol alters brain dopamine metabolism and exacerbates autism-like behaviors in the BTBR mouse. Brain Sciences, 10(4), 233.
pubmed: 32294927
pmcid: 7226382
doi: 10.3390/brainsci10040233
Pietropaolo, S., Bellocchio, L., Bouzón-Arnáiz, I., & Yee, B. K. (2020). The role of the endocannabinoid system in autism spectrum disorders: Evidence from mouse studies. Progress in Molecular Biology and Translational Science, 173, 183–208.
pubmed: 32711810
doi: 10.1016/bs.pmbts.2020.04.016
Pinapati, K. K., Vidya, S., Khan, M. F., Mandal, D., & Banerjee, S. (2024). Gut bacteria, endocannabinoid system, and marijuana addiction: Novel therapeutic implications. Health Sciences Review, 10, 100144.
doi: 10.1016/j.hsr.2023.100144
Poleg, S., Golubchik, P., Offen, D., & Weizman, A. (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 89, 90–96. https://doi.org/10.1016/j.pnpbp.2018.08.030
doi: 10.1016/j.pnpbp.2018.08.030
pubmed: 30171992
Prasad, A., Crowe, M., Burton, G., & McGrew, L. (2020). Anxiolytic effects of cannabinoid receptor agonists in the Zebrafish species, Danio Rerio. The FASEB Journal, 34(S1), 1–1.
doi: 10.1096/fasebj.2020.34.s1.09915
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011). Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nature Neuroscience, 14(10), 1227–1235. https://doi.org/10.1038/nn.2923
doi: 10.1038/nn.2923
pubmed: 21952260
Qin, M., Zeidler, Z., Moulton, K., Krych, L., Xia, Z., & Smith, C. B. (2015). Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behavioural Brain Research, 291, 164–171.
pubmed: 25979787
pmcid: 5003021
doi: 10.1016/j.bbr.2015.05.003
Radyushkin, K., Hammerschmidt, K., Boretius, S., Varoqueaux, F., El-Kordi, A., Ronnenberg, A., Winter, D., Frahm, J., Fischer, J., & Brose, N. (2009). Neuroligin-3-deficient mice: Model of a monogenic heritable form of autism with an olfactory deficit. Genes, Brain and Behavior, 8(4), 416–425.
pubmed: 19243448
doi: 10.1111/j.1601-183X.2009.00487.x
Roux, S., Bailly, Y., & Bossu, J. L. (2019). Regional and sex-dependent alterations in Purkinje cell density in the valproate mouse model of autism. NeuroReport, 30(2), 82–88. https://doi.org/10.1097/wnr.0000000000001164
doi: 10.1097/wnr.0000000000001164
pubmed: 30461560
Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Vigano, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., & Di Marzo, V. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cerebral Cortex, 18(6), 1292–1301.
pubmed: 17921459
doi: 10.1093/cercor/bhm161
Salloum-Asfar, S., Elsayed, A. K., & Abdulla, S. A. (2023). Chapter 6—Potential approaches and recent advances in biomarker discovery in autism spectrum disorders. In A. S. El-Baz & J. S. Suri (Eds.), Neural engineering techniques for autism spectrum disorder (pp. 121–145). Academic Press.
doi: 10.1016/B978-0-12-824421-0.00014-X
Schafer, D. P., Heller, C. T., Gunner, G., Heller, M., Gordon, C., Hammond, T., Wolf, Y., Jung, S., & Stevens, B. (2016). Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression. eLife. https://doi.org/10.7554/eLife.15224
doi: 10.7554/eLife.15224
pubmed: 27458802
pmcid: 4961457
Schiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., & Trezza, V. (2023). Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats. Neuropsychopharmacology, 48(6), 897–907. https://doi.org/10.1038/s41386-022-01454-7
doi: 10.1038/s41386-022-01454-7
pubmed: 36114286
Schneider, M., & Koch, M. (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology, 28(10), 1760–1769.
pubmed: 12888772
doi: 10.1038/sj.npp.1300225
Schneider, M., Schömig, E., & Leweke, F. M. (2008). PRECLINICAL STUDY: Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addiction Biology, 13(3–4), 345–357.
pubmed: 18782382
doi: 10.1111/j.1369-1600.2008.00117.x
Servadio, M., Melancia, F., Manduca, A., di Masi, A., Schiavi, S., Cartocci, V., Pallottini, V., Campolongo, P., Ascenzi, P., & Trezza, V. (2016). Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. Translational Psychiatry, 6(9), e902. https://doi.org/10.1038/tp.2016.182
doi: 10.1038/tp.2016.182
pubmed: 27676443
pmcid: 5048215
Shamabadi, A., Karimi, H., Arabzadeh Bahri, R., Motavaselian, M., & Akhondzadeh, S. (2024). Emerging drugs for the treatment of irritability associated with autism spectrum disorder. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2024.2313650
doi: 10.1080/14728214.2024.2313650
pubmed: 38296815
Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R., & Prather, P. L. (2005). Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. Journal of Pharmacology and Experimental Therapeutics, 315(2), 828–838.
pubmed: 16081674
doi: 10.1124/jpet.105.089474
Siniscalco, D., Sapone, A., Giordano, C., Cirillo, A., de Magistris, L., Rossi, F., Fasano, A., Bradstreet, J. J., Maione, S., & Antonucci, N. (2013). Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. Journal of Autism and Developmental Disorders, 43(11), 2686–2695. https://doi.org/10.1007/s10803-013-1824-9
doi: 10.1007/s10803-013-1824-9
pubmed: 23585028
Sipe, J. C., Arbour, N., Gerber, A., & Beutler, E. (2005). Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders. Journal of Leukocyte Biology, 78(1), 231–238.
pubmed: 15845647
doi: 10.1189/jlb.0205111
Sperlágh, B., Windisch, K., Andó, R. D., & Vizi, E. S. (2009). Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochemistry International, 54(7), 452–457.
pubmed: 19428788
doi: 10.1016/j.neuint.2009.01.017
Strange, P. G. (2002). Mechanisms of inverse agonism at G-protein-coupled receptors. Trends in Pharmacological Sciences, 23(2), 89–95.
pubmed: 11830266
doi: 10.1016/S0165-6147(02)01993-4
Su, T., Yan, Y., Li, Q., Ye, J., & Pei, L. (2021). Endocannabinoid system unlocks the puzzle of autism treatment via microglia. Frontiers in Psychiatry, 12, 734837.
pubmed: 34744824
pmcid: 8568770
doi: 10.3389/fpsyt.2021.734837
Südhof, T. C. (2008). Neuroligins and neurexins link synaptic function to cognitive disease. Nature, 455(7215), 903–911.
pubmed: 18923512
pmcid: 2673233
doi: 10.1038/nature07456
Suzuki, K., Sugihara, G., Ouchi, Y., Nakamura, K., Futatsubashi, M., Takebayashi, K., Yoshihara, Y., Omata, K., Matsumoto, K., & Tsuchiya, K. J. (2013). Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry, 70(1), 49–58.
pubmed: 23404112
doi: 10.1001/jamapsychiatry.2013.272
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., & Yamamoto, A. (2014). Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron, 83(5), 1131–1143.
pubmed: 25155956
pmcid: 4159743
doi: 10.1016/j.neuron.2014.07.040
Tartaglia, N., Bonn-Miller, M., & Hagerman, R. (2019). Treatment of fragile X syndrome with cannabidiol: A case series study and brief review of the literature. Cannabis and Cannabinoid Research, 4(1), 3–9.
pubmed: 30944868
pmcid: 6446166
doi: 10.1089/can.2018.0053
Trezza, V., Damsteegt, R., Manduca, A., Petrosino, S., Van Kerkhof, L. W., Pasterkamp, R. J., Zhou, Y., Campolongo, P., Cuomo, V., & Di Marzo, V. (2012). Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. Journal of Neuroscience, 32(43), 14899–14908.
pubmed: 23100412
doi: 10.1523/JNEUROSCI.0114-12.2012
Trezza, V., & Vanderschuren, L. J. (2008). Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (berl), 197(2), 217–227.
pubmed: 18058088
doi: 10.1007/s00213-007-1025-3
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology, 57(1), 67–81. https://doi.org/10.1002/ana.20315
doi: 10.1002/ana.20315
pubmed: 15546155
Wang, M., Li, H., Takumi, T., Qiu, Z., Xu, X., Yu, X., & Bian, W.-J. (2017). Distinct defects in spine formation or pruning in two gene duplication mouse models of autism. Neuroscience Bulletin, 33(2), 143–152.
pubmed: 28258509
pmcid: 5360848
doi: 10.1007/s12264-017-0111-8
Wang, W. Y., Tan, M. S., Yu, J. T., & Tan, L. (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med, 3(10), 136. https://doi.org/10.3978/j.issn.2305-5839.2015.03.49
doi: 10.3978/j.issn.2305-5839.2015.03.49
pubmed: 26207229
pmcid: 4486922
Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., & Piomelli, D. (2016). Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis and Cannabinoid Research, 1(1), 81–89. https://doi.org/10.1089/can.2015.0008
doi: 10.1089/can.2015.0008
pubmed: 28861483
pmcid: 5549436
Wen, Z., Nguyen, H. N., Guo, Z., Lalli, M. A., Wang, X., Su, Y., Kim, N.-S., Yoon, K.-J., Shin, J., & Zhang, C. (2014). Synaptic dysregulation in a human iPS cell model of mental disorders. Nature, 515(7527), 414–418.
pubmed: 25132547
pmcid: 4501856
doi: 10.1038/nature13716
Werling, D. M., & Geschwind, D. H. (2013). Sex differences in autism spectrum disorders. Current Opinion in Neurology, 26(2), 146.
pubmed: 23406909
pmcid: 4164392
doi: 10.1097/WCO.0b013e32835ee548
Yang, I., Han, S. J., Kaur, G., Crane, C., & Parsa, A. T. (2010). The role of microglia in central nervous system immunity and glioma immunology. Journal of Clinical Neuroscience, 17(1), 6–10.
pubmed: 19926287
doi: 10.1016/j.jocn.2009.05.006
Yeh, M. L., & Levine, E. S. (2017). Perspectives on the role of endocannabinoids in autism spectrum disorders. OBM Neurobiology, 1(2), 5.
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences, 18(9), 1916.
pubmed: 28880200
pmcid: 5618565
doi: 10.3390/ijms18091916
Zhang, L., & Alger, B. E. (2010). Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. Journal of Neuroscience, 30(16), 5724–5729.
pubmed: 20410124
doi: 10.1523/JNEUROSCI.0795-10.2010
Zou, M., Liu, Y., Xie, S., Wang, L., Li, D., Li, L., Wang, F., Zhang, Y., Xia, W., & Sun, C. (2021). Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder. Open Biology, 11(2), 200306.
pubmed: 33529552
pmcid: 8061688
doi: 10.1098/rsob.200306
Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19030833
doi: 10.3390/ijms19030833
pubmed: 30597923
pmcid: 6337518